What are ALK inhibitor drugs?

ALK inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting ALK). 1 are currently marketed, with 7 more in clinical development.

What are the marketed ALK inhibitor drugs?

Marketed ALK inhibitor drugs include Lorlatinib with chemotherapy 2.

ALK inhibitor

1 marketed 1 in Phase 3 6 in Phase 2

This page covers all ALK inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting ALK, ALK (anaplastic lymphoma kinase).

Targets

ALK · ALK (anaplastic lymphoma kinase)

Marketed (1)

Lorlatinib with chemotherapy 2 · Pfizer · Oncology · 798

Phase 3 pipeline (1)

Neladalkib (NVL-655) · Nuvalent Inc. · Oncology
Neladalkib is a selective ALK (anaplastic lymphoma kinase) inhibitor that blocks ALK-driven signaling in cancer cells.

Phase 2 pipeline (6)

ARQ 501 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Oncology
ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.
Alectinib - Usual · Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · Oncology
Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein.
ASP2215 · Astellas Pharma Global Development, Inc. · Oncology
ASP2215 is a selective and potent inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.
ALK tree AIT 7 DU · ALK-Abelló A/S · Oncology
ALK tree AIT 7 DU is a targeted therapy that works by inhibiting the anaplastic lymphoma kinase (ALK) protein.
Any FDA Approved ALK Inhibitors · Takeda · Oncology
ALK tyrosine kinase inhibitor
ALK tree AIT 1 DU · ALK-Abelló A/S · Oncology
ALK tree AIT 1 DU is a targeted therapy that works by inhibiting the anaplastic lymphoma kinase (ALK) protein.